KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Gross Profit (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Gross Profit data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Gross Profit fell 88.61% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $15.7 million, down 70.04%, while the annual FY2024 figure was $56.4 million, 0.05% changed from the prior year.
  • Gross Profit reached $1.5 million in Q3 2025 per NKTR's latest filing, down from $11.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $20.7 million in Q2 2021 and bottomed at -$6.8 million in Q1 2025.
  • Average Gross Profit over 5 years is $13.4 million, with a median of $14.5 million recorded in 2023.
  • Peak YoY movement for Gross Profit: rose 11.94% in 2024, then tumbled 165.17% in 2025.
  • A 5-year view of Gross Profit shows it stood at $18.8 million in 2021, then decreased by 16.22% to $15.8 million in 2022, then grew by 5.14% to $16.6 million in 2023, then crashed by 40.75% to $9.8 million in 2024, then tumbled by 84.82% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $1.5 million in Q3 2025, $11.2 million in Q2 2025, and -$6.8 million in Q1 2025.